Massachusetts-based SpectraWAVE has gained considerable momentum in recent years, planting its flag in some of cardiology’s biggest trends. The company was co-founded by cardiologists and has already secured multiple FDA clearances.
San Diego-based Vektor Medical first secured FDA clearance for the AI-powered technology back in 2021. This updated announcement covers the latest version, which includes atrial flutter mapping and several other new features.
These most recent recalls focus on a series of maintenance issues. In 2024, the FDA advised customers to transition away from the two devices and find alternative treatment options.
Image courtesy of the Independent Medical Alliance.
Kirk Milhoan, MD, PhD, has been fired from his role as a pediatric cardiologist. His wife and others say he was let go because he is now the chair of the CDC’s Advisory Committee on Immunization Practices.
The Barostim Neo 2 CVRx heart failure nerve stimulator device, showing how the electrode attaches to to baroreceptors located on the carotid artery.
The Barostim device from CVRx continues to gain momentum as a go-to heart failure treatment. A free webinar is scheduled to examine the device's new CPT codes, which go into effect in 2026.
HeartFlow Plaque analysis AI software highlighting areas of interest in the coronaries with significant plaque burden and showing a cross sectional reformatted view with plaques.
For years, imaging experts have predicted that CCTA may become the primary imaging modality for coronary artery disease and eliminate the need for invasive diagnostic catheterizations. That prediction is now coming true.
